Login
Login     |     Register     |     Recover Username/Password

News

Acute Myeloid Leukemia (AML) Treatment in Phase III Trials: Cyclacel (CYCC) CEO and CFO Buy Stock

May 23, 2013

There have been several highly successful biotech companies formed from the patent libraries of universities and from research institutes. Often these are private companies owned by the clinical researchers and the institutions that fund them, but occasionally these companies are registered in the public markets and are available for general investment. Cyclacel Pharmaceuticals (CYCC) was formed in 1997 to exploit several biotech innovations developed at the University of Dundee. In an interview from September of last year in The Wall Street Transcript, Spiro Rombotis, President and CEO of Cyclacel Pharmaceuticals, stated that, “Our lead drug, sapacitabine, is now in a pivotal Phase III trial for acute myeloid leukemia, or AML, a disease of mostly elderly people… sapacitabine offers to patients with AML … the first drug in its class to be given by mouth...
more

Institutional Investor Support and Insider Buying Make Holly Energy Partners, L.P. (HEP) Compelling

May 22, 2013

Christopher C. Grisanti is a magna cum laude graduate of Harvard Law School who gave up his partnership track law career at Simpson Thacher & Bartlett to become a professional stock picker.  He’s now the Owner and Co-Founder of Grisanti Capital Management.  In an interview on February 15, 2013, Grisanti cites HollyFrontier Corp (HFC) as a top pick: “Many of the Wall Street analysts that have analyzed these refiners for 30 years don’t want to say things are different. They have a picture of refineries as very cyclical companies, but I think they don’t appreciate that there is a secular up trend that will continue, we think, for three or four more years that will help these guys earn record profits not for six or nine months but for literally half a decade...
more

Rackspace Hosting (RAX) Faces Increased Competition and Growth Uncertainty

May 21, 2013

Rackspace Hosting (RAX) faces increasing competition and uncertainty about the future growth of its cloud business, with the most recent fourth-quarter results showing a revenue growth outlook which implied lower capex guidance than the Street hoped for, says Todd Weller, Managing Director at Stifel, Nicolaus & Co., Inc. “We decided to downgrade the stock after we had a great multiyear run with it. I think at this point we remain more cautious than optimistic, and again some of that is just we feel that to become more constructive, we need to have a better understanding of what sustainable growth looks like, because again, things seem to have changed — and trying to figure out if they’re a low 20% grower or high-teens grower, or how to think about that,” Weller said...
more

Facebook (FB) Faces Increasingly Fragmented Audience

May 21, 2013

Facebook (FB) faces pressures from online audience fragmentation and the loss of eyeballs to other more mobile platforms such as Twitter, Snapchat and WhatsApp, says Brian Pitz, Managing Director and Senior Research Analyst at Jefferies & Company, Inc. “We were concerned in terms of some of the engagement metrics; the data we have suggests that the Millennial demographic might be churning off a bit faster than other demographics, which are shifting to more mobile-centric apps and/or platforms. We think Facebook tried to address this early on through its acquisition of Instagram, but what is happening since then is further fragmentation of the audience onto other platforms or apps such as Twitter, Snapchat or WhatsApp,” Pitz said...
more

Electronic Arts Inc.’s (EA) Battlefield to Compete with Activision’s (ATVI) Call of Duty, Yet Real Opportunity is Va

May 21, 2013

Electronic Arts Inc. (EA) holds a number of core franchises in the electronic gaming field, with “Battlefield” set to compete against Activision‘s “Call of Duty” this holiday season, yet the real opportunities for EA remain unclear as the company struggles to remain profitable in an increasingly competitive industry that is also going through a console transition, says Brian Pitz, Managing Director and Senior Research Analyst at Jefferies & Company, Inc. “Activision (ATVI) is the best-in-breed core gaming company, and we believe that EA (EA) has a couple of great core franchises like ‘FIFA Soccer,’ ‘Madden’ football and ‘Battlefield...
more
Page 1 | Next 5 | Page 201
TSWT - Subscribe now!

The Wall Street Transcript is a completely unique resource for investors and business researchers.

Over 20,000 CEO, Equity Analyst and Money Manager Interviews

TWST Newsletter

Weekly email with New In-Depth Interviews

Most Popular Interviews
Opportunities in Hepatitis C and Genomic Technologies
David Ferreiro

Published April 26, 2014 in Biotechnology and Pharmaceuticals

Buy ($75)
Investing in Health Care Innovation
Finny Kuruvilla

"We’re a faith-based and socially responsible investing firm"

Published May 16, 2013 in Investing in Health Care

Buy ($75)
A Health Sciences Fund with a Long-Term Focus
Mark W. Oelschlager

"The fund is about $40 million in assets"

Published May 16, 2013 in Investing in Health Care

Buy ($75)
High-Yield Canadian Power Companies
John McIlveen

Published May 14, 2013 in High-Yield Equity Securities

Buy ($75)
Most Popular Reports
Investing in Health Care

Published May 16, 2013

Topics Covered: Health Care - Electronic Health Record Adoption - Biotechnology and Pharmaceutical Investing - Biotechnology and Pharmaceuticals - Biotechnology and Pharmaceutical Companies Valuation - Platform Interoperability and Data Analytics - HITECH Act Incentives - Affordable Care Act
Buy ($175)
Internet Services

Published May 10, 2013

Topics Covered: Increased Mobile Content Traffic - Chinese Online Monetization Trends - Internet Infrastructure and Services Consolidation - Social Networking Economics -
Buy ($175)
Investing Strategies

Published May 10, 2013

Topics Covered: Investing in Financial Services - Long-Term Investing - Large Cap Investing - Value Investing - High Quality Companies - Bottom-up Investing - All-Cap Growth Investing - Investing in Emerging Markets
Buy ($175)
Top Company Interviews
TWST
Register for a Free Account to gain greater access to The Wall Street Transcript right now